Skip to main content
Critical Care logoLink to Critical Care
. 2005 Mar 7;9(Suppl 1):P35. doi: 10.1186/cc3098

The removal of antibiotics during continuous venovenous hemofiltration (CVVH) in critically ill patients with acute renal failure: measured versus estimated CVVH clearance

C Bouman 1, H Kan 1, M Schultz 1, M Vroom 1
PMCID: PMC4098185

Background

The clearance of antibiotics during continuous venovenous hemofiltration (CVVH) is calculated by multiplying the sieving coefficient (SC) (defined as the ratio of drug concentration in the ultrafiltrate to plasma) and the ultrafiltration rate (Quf). For most antibiotics the SC is unknown. It was suggested that the SC can be substituted by the non-protein-bound fraction (fu). However, fu values as reported in the literature are determined in healthy volunteers and not during critical illness. We compared measured and estimated CVVH clearance (ClCVVH) of five antibiotics.

Methods

In 40 patients with ARF undergoing CVVH (predilution, cellulose-triacetate filter, Quf 36 ± 8 ml/min), prefilter, postfilter and ultrafiltrate samples were collected and drug concentrations were determined by HPLC or by immunoassay. The prefilter concentration (Cpre) was corrected using the dilution factor (Qb/Qb + Qinf), where Qb is the blood flow rate and Qinf is the substitution fluid infusion rate. The SC was calculated as follows: SC = 2 × Cuf / (Cpre + Cpost).

Results

Data (mean ± standard deviation) are presented in Table 1. ClCVVH (ml/min) was calculated by multiplying the SC (or the fu) and the Quf.

Table 1.

Drug (n) Measured SC Measured ClCVVH Non-protein-bound fraction Estimated ClCVVH
Ceftazidim (4) 2.14 ± 2.64 75 ± 92 0.79 28 ± 1
Ciprofloxacine (16) 0.89 ± 0.33 31 ± 12 0.60 21 ± 1
Flucloxacilline (5) 0.37 ± 0.38 13 ± 14 0.20 7 ± 0
Fluconazol (9) 0.86 ± 0.09 30 ± 2 0.88 31 ± 1
Vancomycine (6) 0.71 ± 0.19 27 ± 5 0.70 28 ± 9

SC, sieving coefficient; ClCVVH, continuous venovenous hemofiltration clearance.

Conclusions

Measured and estimated ClCVVH corresponded well for fluconazol and vancomycine, but not for ceftazidim, ciprofloxacine and flucloxacilline, possibly due to changes in protein binding induced by critical illness or drug–membrane interactions. Therefore, for antibiotics with a narrow therapeutic range, monitoring drug concentrations remains mandatory.


Articles from Critical Care are provided here courtesy of BMC

RESOURCES